Amantadine in the treatment of Parkinson's disease and other movement disorders
Review discusses the pharmacological profile of amantadine and covers evidence from RCTs for the use of this drug for levodopa-induced dyskinesias in patients with Parkinson’s disease. It notes use for drug induced Parkinsonism and tardive dyskinesia lack a strong evidence base.
Source:
The Lancet Neurology
SPS commentary:
A related commentary notes the article provides insights into the reasons why amantadine is not widely used, highlighting that the complex pharmacology is still not fully understood, as well as the mechanisms behind its beneficial effects.